Slides
Page 1
YTD/Q3 2026 RESULTS 28-Oct-2026 OLIVIER RIGAUD (CEO) PETER KAZIUS (CFO)
Page 2
28/10/2026 YTD/Q3 2026 RESULTS 2 This presentation contains forward-looking statements with respect to Corbion’s future performance and position. Such statements are based on current expectations, estimates, and projections of Corbion and information currently available to the company. Corbion cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Also, for a variety of reasons including many factors outside the control of Corbion, there can be no guarantee that any proposed strategic initiatives will be completed within the expected time frame or at all. Nor can there be any guarantee that Corbion will be able to realize any of the potential strategic benefits, synergies, or opportunities, or any guarantee that shareholders will achieve any particular level of return in relation thereto. Corbion ha s no obligation to update the statements contained in this presentation, unless required by law. More details on Corbion’s H1 2026 financial performance can be found in the Q3 2026 press release. A more comprehensive discussion of the risk factors affecting Corbion’s business is available in the company’s Annual Report 2025. This presentation to investors includes alternative performance measures (APMs), and information that is presented in accordance with IFRS as issued by the International Accounting Standards Board (‘IFRS figures’).
Page 3
• YTD Organic sales growth of +3.9% to € 971.6 million (Q3: +7.6%, € 340.5 million) • Volume/mix +5.3% (Q3: +7.9%) • Pricing -1.4% (Q3: -0.3%) • YTD Adjusted EBITDA € 152.9 million (Q3: € 64.1 million) • Health & Nutrition: Q3 organic sales growth of +20.0% and Adjusted EBITDA margin increased +400 bps to +38.1%, driven by strong Nutrition volume recovery and favorable mix • Functional Ingredients & Solutions: YTD organic sales growth at high-end of forecasted range at +3.8% (Q3: +4.0%) and Adjusted EBITDA margin up +170 bps to 11.0% (Q3: 12.5%). • Strong free cash flow generation in Q3 • FY 2026 outlook affirmed YTD/Q3 2026 Highlights +3.9% (YTD) +7.6% (Q3) Organic sales growth Adj. EBITDA margin Free Cash Flow 15.7% (YTD) 18.8% (Q3) € 57.0 m (YTD) € 61.0 m (Q3) YTD/Q3 2026 RESULTS 3 28/10/2026
Page 4
4 Sales growth per segment in YTD/Q3 2026 YTD/Q3 2026 RESULTS 28/10/2026
Page 5
5 Sales and Adjusted EBITDA: YTD/Q3 2026 YTD/Q3 2026 RESULTS 28/10/2026
Page 6
28 9 23 6 YTD Sales and Adjusted EBITDA development Sales YTD Adjusted EBITDA YTD Q1: -€ 2 million Q2: +€ 20 million Q3: +€ 10 million Q1: -€ 12 million Q2: +€ 7 million Q3: +€ 14 million *Continued operations for 2024 YTD/Q3 2026 RESULTS 28/10/2026 1,000 960 10 970 990 950 980 0 Q3 YTD 2025 FI&S H&N FX Q3 YTD 2026 972 957 +1.5% 5 9 165 150 0 160 5 155 Q3 YTD 2025 Organic Acq./ Div FX Q3 YTD 2026 153 156 0 -2.2% € million € million 930 940 135 145 140 Q1: -€ 11 million Q2: +€ 2 million Q3: +€ 14 million 1,010 170
Page 7
Functional Ingredients & Solutions Q3 volume/mix growth of 3.7% Q3 EBITDA margin up +170 bps to 12.5% YTD +3.8% YTD 11.0% YTD organic sales growth of +3.8% (Q3: +4.0%) • Volume/mix +4.1% (Q3: +3.7%) Food: growth in natural preservation, vinegars and high-protein bakery, with soft meat and confectionery demand. Natural mold inhibitors and enzyme blends continued to grow. Biochemicals: strong YTD and Q3 sales growth continued from H1 Lactic Acid to PLA: higher volumes to the JV drove growth, with lower pass-through pricing • Pricing -0.3% YTD (Q3: +0.3%), with Q3 pricing initiatives supporting the increase Adjusted EBITDA margin 11.0%, -50 bps (Q3: 12.5%, +170 bps) • YTD margin pressure from lower-margin business mix. • Q3 margin improvement driven by cost-reduction initiatives and operational efficiencies. • Sequential margin increase versus Q2 +100bps 7 YTD/Q3 2026 RESULTS 28/10/2026 12.1 11.7 10.8 9.8 9.0 11.5 12.5 Q1-25 Q2-25 Q3-25 Q4-25 Q1-26 Q2-26 Q3-26 Adjusted EBITDA margin Functional Ingredient & Solutions € million YTD 2026 YTD 2025 Q3 2026 Q3 2025 Sales 748.7 739.8 256.0 242.3 Organic growth +3.8% +1.5% +4.0% +0.8% Adjusted EBITDA 82.6 85.2 31.9 26.1 Adjusted EBITDA margin 11.0% 11.5% 12.5% 10.8% 5.8 -1.8 0.8 0 -0.8 8.4 4.0 Q1-25 Q2-25 Q3-25 Q4-25 Q1-26 Q2-26 Q3-26 Org sales growth - Functional Ingredients & Solutions (%) (%)
Page 8
Health & Nutrition Q3 organic sales +20.0% on Nutrition volume phasing Q3 adj. EBITDA margin 38.1%, +400 bps YoY YTD organic sales growth of +4.1% (Q3: +20.0%) • Volume/mix +9.0% (Q3: +22.3%) Nutrition: Strong Q3 growth reflected anticipated volume phasing from H1 2026. Higher fish oil prices lifted omega-3 DHA prices, with new-customer sales mainly reflected in mix. Pharma: YTD and Q3 sales declined on lower volume/mix and 2026 destocking at key customers in North and Latin America. Biomaterials: YTD sales rose on higher volume/mix and pricing. In October, Medincell and Teva announced FDA approval of WELTRUZA (olanzapine), the first and only once- monthly subcutaneous olanzapine for adults with schizophrenia, supporting Corbion’s BRIGHT 2030 sales growth ambition. • Pricing -4.9% (Q3: -2.3%) YTD Adjusted EBITDA margin 31.5%, -120 bps (Q3: 38.1%, +400 bps). YTD 2026 Adjusted EBITDA declined -1.1% to €70.3m but rose at constant currency. Q3 grew 36.4% year-on-year, driven by favorable mix and strong Nutrition volume recovery after phasing. YTD/Q3 2026 RESULTS 8 28/10/2026 16.2 -0.6 -11.2 24.9 -15.8 8.7 20.0 Q1-25 Q2-25 Q3-25 Q4-25 Q1-26 Q2-26 Q3-26 Org sales growth - Health & Nutrition YTD +4.1% € million YTD 2026 YTD 2025 Q3 2026 Q3 2025 Sales 222.9 217.4 84.5 69.3 Organic growth +4.1% +0.1% +20.0% -11.2% Adjusted EBITDA 70.3 71.1 32.2 23.6 Adjusted EBITDA margin 31.5% 32.7% 38.1% 34.1% 32.2 32.0 34.1 32.0 28.6 26.8 38.1 Q1-25 Q2-25 Q3-25 Q4-25 Q1-26 Q2-26 Q3-26 Adjusted EBITDA margin Health & Nutrition (%) (%) YTD 31.5% WELTRUZA is a registered trademark of Teva Pharmaceuticals
Page 9
TotalEnergies Corbion joint venture *Results on 100% basis. Corbion owns 50% of TotalEnergies Corbion joint venture Q3 organic sales growth +29.5% Q3 EBITDA margin 8.2%, +30 bps YoY YTD organic sales growth +24.2% (Q3: +29.5%) • Sales €120.7m vs €100.9m YTD 2025 (Q3: €41.6m vs €31.6m). YTD EBITDA margin 7.7%, -130 bps (Q3: 8.2%, +30 bps) • EBITDA €9.3m vs €9.1m YTD 2025 (Q3: €3.4m vs €2.5m). PLA divestment process discontinued • Offers did not reflect the business’s value, strategic position and long-term potential. • Corbion will develop the business under current ownership and improve performance as PLA market dynamics strengthen. YTD/Q3 2026 RESULTS YTD +24.2% YTD 7.7% 9 € million 28/10/2026 € million * YTD 2026 YTD 2025 Q3 2026 Q3 2025 Sales 120.7 100.9 41.6 31.6 Orga ni c growth +24.2% +4.3% +29.5% +1.6% EBITDA 9.3 9.1 3.4 2.5 EBITDA mar gin 7.7% 9.0% 8.2% 7.9% Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Sales - TotalEnergies corbion (%) Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Adjusted EBITDA margin TotalEnergies corbion C C
Page 10
Organic sales growth: +3-6% Adjusted EBITDA margin: >16% Free Cash Flow*: € 85-90 million CapEx spend 2026-2028: ~6% of sales 10 * Free Cash Flow = Cash Flow from operating activities -/- Cash Flow from investment activities (excluding acquisitions/disposals) FY 2026 guidance maintained H1/Q2 2026 RESULTS 31/07/2026 • Strong Q3 and Q4 orderbook visibility support full-year guidance. • FY organic sales growth in both segments: continued Q4 FI&S growth and mid-single-digit-% H&N growth. • FY Adjusted EBITDA margin >16%. Q4 margins: FI&S below Q3 on seasonality and Middle East-related costs, H&N broadly stable.
Page 11
Investor relations www.corbion.comalex.sokolowski@corbion.com +31 20 590 6341